Zeo ScientifiX (ZEOX) awards CSO 50,000 restricted common shares

Rhea-AI Filing Summary

Zeo ScientifiX, Inc. reported the initial holdings of its Chief Science Officer, David John Kisiday, in a Form 3. He beneficially owns 50,000 shares of common stock, all in the form of restricted stock granted on January 23, 2026 under the company’s 2021 Equity Incentive Plan.

The grant vests over two years, with 20,000 shares vesting on the first anniversary of Mr. Kisiday’s employment agreement effective January 23, 2026 and 30,000 shares vesting on the second anniversary. Vesting is contingent on his continued service and the other terms of the incentive plan.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kisiday John David

(Last) (First) (Middle)

3321 COLLEGE AVENUE

SUITE 246

(Street)

DAVIE FL 33314

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/23/2026

3. Issuer Name and Ticker or Trading Symbol
Zeo ScientifiX, Inc. [ ZEOX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.001 par value	50,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted common stock granted to the Reporting Person on January 23, 2026 under the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The shares vest as to 20,000 shares on the first anniversary of the Reporting Person's employment agreement with the Issuer effective January 23, 2026 (the "Employment Agreement") and 30,000 shares on the second anniversary of the Employment Agreement, subject to the Reporting Person's continued service with the Issuer and the other terms and conditions of the Incentive Plan.

	/s/ David John Kisiday	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Zeo ScientifiX (ZEOX) Form 3 filing disclose?

The Form 3 shows Chief Science Officer David John Kisiday beneficially owning 50,000 shares of Zeo ScientifiX common stock. These shares are restricted stock granted under the 2021 Equity Incentive Plan with a two-year service-based vesting schedule tied to his employment agreement.

How many Zeo ScientifiX (ZEOX) shares does the Chief Science Officer hold?

Chief Science Officer David John Kisiday beneficially owns 50,000 shares of Zeo ScientifiX common stock. All shares are restricted stock granted on January 23, 2026, and are subject to a two-year vesting schedule and the terms of the company’s 2021 Equity Incentive Plan.

What is the vesting schedule for David John Kisiday’s 50,000 ZEOX restricted shares?

The 50,000 restricted shares vest in two tranches tied to his employment agreement effective January 23, 2026. 20,000 shares vest on the first anniversary and 30,000 shares vest on the second anniversary, subject to his continued service and the incentive plan’s conditions.

Under which plan were the Zeo ScientifiX (ZEOX) restricted shares granted?

The restricted shares were granted under Zeo ScientifiX’s 2021 Equity Incentive Plan. The Form 3 notes that 50,000 shares of restricted common stock were awarded to Chief Science Officer David John Kisiday on January 23, 2026, with vesting dependent on continued service and plan terms.

Is the ownership reported in the Zeo ScientifiX (ZEOX) Form 3 direct or indirect?

The Form 3 shows that the 50,000 shares of Zeo ScientifiX common stock are held with direct beneficial ownership. The filing lists the ownership form as “D,” indicating the shares are attributed directly to Chief Science Officer David John Kisiday rather than through an intermediary entity.